These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Aug 6, 2020Commercialization and launch of first royalty bearing products position company for next phase of growth
SAN DIEGO, August 6, 2020 — Pfenex Inc. (NYSE American: PFNX) reported financial results for the second quarter ended June 30, 2020 and provided a business update. “The second quarter of 2020...
-
Jul 20, 2020
SAN DIEGO, July 20, 2020 — Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended June 30, 2020, after the market close on...
-
Jun 26, 2020
Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorization Pfenex’s commercial partner Adalvo entered into...
-
Jun 12, 2020Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States
SAN DIEGO, June 12, 2020 —Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States. Teriparatide...
-
Jun 5, 2020
SAN DIEGO, June 5, 2020 —Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William...
-
May 7, 2020
SAN DIEGO, May 7, 2020 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex...
-
Apr 24, 2020
SAN DIEGO, April 24, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market close on...
-
Apr 14, 2020FDA review for a Therapeutic Equivalency rating for PF708 continues
SAN DIEGO, April 14, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the Company’s...
-
Mar 11, 2020Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® | Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743 (JZP-458) for the treatment of ALL/LBL | Earned $31.1 million in development and regulatory milestone payments in FY 2019
SAN DIEGO, March 11, 2020 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Feb 27, 2020
SAN DIEGO, February 26, 2020 -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the...
-
Jan 8, 2020
SAN DIEGO, January 8, 2020 - Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization (WHO)...
-
Dec 18, 2019
SAN DIEGO, December 18, 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with Jazz...
-
Nov 20, 2019
SAN DIEGO, November 20, 2019 —Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Nov 19, 2019
SAN DIEGO, November 19, 2019 —Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Nov 13, 2019
SAN DIEGO, November 13, 2019 — Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief Financial...
-
Nov 7, 2019Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the therapeutic equivalence rating relative to Forteo® | Announced partnership with Arcellx to develop SparX proteins used in cell therapies | Jazz advances PF743 (JZP-458) to pivotal Phase 2/3 Study expected to be initiated later this year; Jazz also announced FDA fast track designation for JZP-458, for the treatment of ALL/LBL | Earned $13.5 million in development and regulatory milestone payments
SAN DIEGO, November 7, 2019 — Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and...
-
Nov 6, 2019
Conference: Jefferies 2019 London Healthcare Conference Date: Wednesday, November 20, 2019 Time: 4:00 p.m. GMT (8:00 a.m. PST) Webcast: Interested parties can access the live audio webcast and...
-
Oct 24, 2019
SAN DIEGO, October 24, 2019-- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop and improve...
-
Oct 14, 2019Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks | Pfenex believes the study report completes the information package required by the FDA to evaluate the FDA-approved PF708 product for therapeutic equivalence
SAN DIEGO, October 14, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study...
-
Oct 11, 2019New Exclusive Commercialization Agreements in South Korea, Canada, and Israel | Submission of Marketing Authorization Application for PF708 in Saudi Arabia | Potential approval of PF708 in the EU as early as the second half of 2020
SAN DIEGO, October [11], 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea...
-
Oct 7, 2019Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval. Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019
SAN DIEGO, October 7, 2019 — Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved the new drug application (“NDA”) for PF708...
-
Sep 16, 2019
SAN DIEGO, September 16, 2019—Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Sep 10, 2019
SAN DIEGO, September 10, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Sep 5, 2019
SAN DIEGO, September 5, 2019 — Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz...
-
Sep 4, 2019
SAN DIEGO, September 5th, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Aug 8, 2019
SAN DIEGO, August 8, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Aug 8, 2019NDA for PF708 reached the FDA mid-cycle review milestone in May | Positive Phase 1 results for PF743 (JZP-458) and Jazz advances the product to Pivotal Phase 2/3 Study | Agreement with Arcellx Leverages Pfēnex Expression Technology® platform
SAN DIEGO, August 8, 2019 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Aug 1, 2019First Arcellx sparX protein successfully completed process development using Pfēnex Expression Technology® platform | Second sparX program initiated by Arcellx
SAN DIEGO, August 1, 2019 —Pfenex Inc. (NYSE American: PFNX) and Arcellx, Inc. today announced a Development, Evaluation and License agreement under which Arcellx gains access to the proprietary Pfe
-
Jul 25, 2019
SAN DIEGO, July 25, 2019-- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
Jun 5, 2019
SAN DIEGO, June 5, 2019 —Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
May 30, 2019Distribution and promotion by established regional partner Theramex
SAN DIEGO, May 30, 2019 —Pfenex Inc. (NYSE American: PFNX) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA)...
-
May 9, 2019PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors
SAN DIEGO, May 9, 2019 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
-
Apr 25, 2019
SAN DIEGO, April 25, 2019-- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
Apr 23, 2019
SAN DIEGO, April 23, 2019 —Pfenex Inc. (NYSE American: PFNX), today announced the appointment of Robert Peach, Ph.D. to the Pfenex Scientific Advisory Board. “We are very excited to have Dr....
-
Apr 11, 2019No 30-month Litigation Stay Delaying Approval
San Diego, California – April 11, 2019 – Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression...
-
Mar 27, 2019
SAN DIEGO, March 27, 2019—Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
Mar 25, 2019
SAN DIEGO, March 26, 2019 —Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
Mar 18, 2019
SAN DIEGO, March 18,2019—Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
Mar 11, 2019We believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors. Several significant milestones across the Company’s pipeline are expected in 2019
SAN DIEGO, March 11, 2019 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Mar 6, 2019Serum Institute of India first Licensee to complete a Phase 3 clinical trial with CRM197 produced in Pfēnex Expression Technology®
SAN DIEGO, March 6, 2019—Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (SIIPL), has completed a pivotal Phase 3 study for Pneumosil® a...
-
Mar 4, 2019
SAN DIEGO, March 4, 2019 —Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve...
-
Feb 28, 2019Distribution and Promotion by established regional players Theramex and Tamer Group (SAJA)
Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW Distribution and Promotion...
-
Feb 25, 2019
SAN DIEGO, February 25, 2019-- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to...
-
Feb 19, 2019FDA Sets PDUFA Date of October 7, 2019
SAN DIEGO, February 19, 2019 —Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the 505(b)(2) New Drug Application (NDA)...
-
Dec 10, 2018Submitted as a 505(b)(2) NDA with an Expected Ten-Month Review
SAN DIEGO, December 10, 2018-- Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of...
-
Nov 7, 2018On track to submit the NDA for PF708 to the FDA in fourth quarter of 2018
SAN DIEGO, November 7, 2018 —Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to...
-
Oct 25, 2018
SAN DIEGO, California – October 25, 2018 -- Pfenex Inc. (NYSE AMERICAN: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression...
-
Oct 1, 2018
SAN DIEGO, October 1, 2018 — Pfenex Inc. (NYSE American: PFNX) (“Pfenex” or the “Company”), a clinical-stage development and licensing biotechnology company focused on leveraging its...
-
Sep 21, 2018
SAN DIEGO, September 21, 2018 —Pfenex Inc. (NYSE American: PFNX) announced today that it will be presenting at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York. President and...